Pharming Group NV banner

Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 1.342 EUR 0.07% Market Closed
Market Cap: €941.3m

Pharming Group NV
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pharming Group NV
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Pharming Group NV
AEX:PHARM
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
EPS (Diluted)
€0
CAGR 3-Years
25%
CAGR 5-Years
17%
CAGR 10-Years
5%
Uniqure NV
NASDAQ:QURE
EPS (Diluted)
-$3
CAGR 3-Years
-8%
CAGR 5-Years
-4%
CAGR 10-Years
1%
argenx SE
XBRU:ARGX
EPS (Diluted)
$19
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
EPS (Diluted)
-$5
CAGR 3-Years
-54%
CAGR 5-Years
-12%
CAGR 10-Years
-11%
LAVA Therapeutics NV
NASDAQ:LVTX
EPS (Diluted)
$0
CAGR 3-Years
26%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
No Stocks Found

Pharming Group NV
Glance View

Market Cap
941.3m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.242 EUR
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Pharming Group NV's EPS (Diluted)?
EPS (Diluted)
0 USD

Based on the financial report for Dec 31, 2025, Pharming Group NV's EPS (Diluted) amounts to 0 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett